yttrium (90Y) besilesomab barzuxetan

Yttrium (90Y) besilesomab barzuxetan (also known as TLX66 or 90Y-besilesomab) is an investigational targeted radioimmunotherapy being developed by Telix Pharmaceuticals for bone marrow conditioning prior to hematopoietic stem cell transplantation (HSCT). It consists of besilesomab, a murine IgG1 monoclonal antibody that targets CD66 (specifically binding to CEACAM1, CEACAM5, CEACAM6, and CEACAM8), conjugated via the bifunctional chelator barzuxetan (a DTPA derivative) to the beta-emitting radioisotope yttrium-90. By targeting CD66-expressing granulocytes and myeloid-lineage cells, the drug selectively delivers cytotoxic beta radiation to the red bone marrow, enabling bone marrow ablation with reduced systemic toxicity compared to conventional chemotherapy-based conditioning. It is currently in Phase II clinical development for pediatric leukemia, multiple myeloma, and systemic AL amyloidosis.

Other names

90Y-anti-CD6690Y-besilesomab90Y-DTPA-besilesomabbesilesomab barzuxetan yttrium-90yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183yttrium Y 90 besilesomab barzuxetanyttrium-90 anti-CD66 antibodyyttrium90 anti-CD66 antibodyyttrium 90 anti-CD66 antibodyyttrium-90 besilesomabyttrium90 besilesomabyttrium 90 besilesomabyttrium-90 besilesomab barzuxetanyttrium90 besilesomab barzuxetanyttrium 90 besilesomab barzuxetan